Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CAPS's Cash to Debt is ranked higher than
95% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CAPS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CAPS' s 10-Year Cash to Debt Range
Min: 0.36  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
CAPS's Interest Coverage is ranked higher than
90% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CAPS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CAPS' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -83.85
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -95.41
CAPS's ROE (%) is ranked lower than
79% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CAPS: -95.41 )
Ranked among companies with meaningful ROE (%) only.
CAPS' s 10-Year ROE (%) Range
Min: -86.35  Med: -27.88 Max: 84.13
Current: -95.41
-86.35
84.13
ROA (%) -87.47
CAPS's ROA (%) is ranked lower than
83% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. CAPS: -87.47 )
Ranked among companies with meaningful ROA (%) only.
CAPS' s 10-Year ROA (%) Range
Min: -77.87  Med: -26.73 Max: 78.94
Current: -87.47
-77.87
78.94
ROC (Joel Greenblatt) (%) -3940.85
CAPS's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. CAPS: -3940.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CAPS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8846.82  Med: -1873.23 Max: 0.82
Current: -3940.85
-8846.82
0.82
EBITDA Growth (3Y)(%) -22.90
CAPS's EBITDA Growth (3Y)(%) is ranked lower than
74% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. CAPS: -22.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CAPS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.8  Med: -7.25 Max: 87.4
Current: -22.9
-36.8
87.4
EPS Growth (3Y)(%) -25.30
CAPS's EPS Growth (3Y)(%) is ranked lower than
73% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CAPS: -25.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CAPS' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.8  Med: -5.55 Max: 108
Current: -25.3
-41.8
108
» CAPS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CAPS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.50
CAPS's P/B is ranked higher than
63% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. CAPS: 3.50 )
Ranked among companies with meaningful P/B only.
CAPS' s 10-Year P/B Range
Min: 0.04  Med: 0.23 Max: 3.84
Current: 3.5
0.04
3.84
Current Ratio 5.95
CAPS's Current Ratio is ranked higher than
59% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CAPS: 5.95 )
Ranked among companies with meaningful Current Ratio only.
CAPS' s 10-Year Current Ratio Range
Min: 2.57  Med: 15.68 Max: 140.04
Current: 5.95
2.57
140.04
Quick Ratio 5.95
CAPS's Quick Ratio is ranked higher than
60% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CAPS: 5.95 )
Ranked among companies with meaningful Quick Ratio only.
CAPS' s 10-Year Quick Ratio Range
Min: 1.8  Med: 15.68 Max: 140.04
Current: 5.95
1.8
140.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.00
CAPS's Price/Net Cash is ranked higher than
59% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. CAPS: 6.00 )
Ranked among companies with meaningful Price/Net Cash only.
CAPS' s 10-Year Price/Net Cash Range
Min: 0.39  Med: 1.87 Max: 181.26
Current: 6
0.39
181.26
Price/Net Current Asset Value 4.50
CAPS's Price/Net Current Asset Value is ranked higher than
66% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. CAPS: 4.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CAPS' s 10-Year Price/Net Current Asset Value Range
Min: 0.38  Med: 2.38 Max: 12.16
Current: 4.5
0.38
12.16
Price/Tangible Book 4.50
CAPS's Price/Tangible Book is ranked higher than
55% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CAPS: 4.50 )
Ranked among companies with meaningful Price/Tangible Book only.
CAPS' s 10-Year Price/Tangible Book Range
Min: 0.36  Med: 1.87 Max: 10.47
Current: 4.5
0.36
10.47
Earnings Yield (Greenblatt) (%) -54.30
CAPS's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CAPS: -54.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CAPS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -119.9  Med: 22.50 Max: 33715.6
Current: -54.3
-119.9
33715.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Capstone Therapeutics Corp was incorporated as a Delaware corporation in July 1987 as IatroMed, Inc. On May 21, 2010 the name was changed to Capstone Therapeutics Corp. It is a biotechnology company which develops a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. On August 3, 2012, it entered into a joint venture, LipimetiX Development, LLC, to develop Apo E mimetic peptide molecule AEM-28 and its analogs. Its development activities represent a single operating segment as they shared the same product development path and utilized the same company resources. The biotechnology companies and public institutions compete with the Company in recruiting for research personnel and subjects, which affect its ability to complete research studies.
» More Articles for CAPS

Headlines

Articles On GuruFocus.com
Orthologic Corp. Reports Operating Results (10-Q) Nov 10 2010 
Orthologic Corp. Reports Operating Results (10-Q) Aug 09 2010 
Orthologic Corp. Reports Operating Results (10-Q) Nov 09 2009 
Orthologic Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 22 2015
Capstone Therapeutics Corp. Q1 2015 Operating Update Call scheduled for 4:30 pm ET today Jun 19 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 02 2015
Capstone Therapeutics Announces Settlement of Qui Tam Lawsuit Jun 02 2015
Capstone Therapeutics Corp Earnings Call scheduled for 4:30 pm ET today May 28 2015
CAPSTONE THERAPEUTICS CORP. Financials May 22 2015
Capstone Therapeutics Announces First Quarter 2015 Financial Results and Operating Update Conference... May 22 2015
10-Q for Capstone Therapeutics Corp. May 17 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-Q, Quarterly Report May 14 2015
10-K for Capstone Therapeutics Corp. May 04 2015
Capstone Therapeutics, Inc. - "Following the Data" Apr 27 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 26 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-K, Annual Report Mar 16 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 30 2015
Capstone Could Succeed with AEM-28 Where Aegerion and Sanofi Failed Jan 28 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 06 2015
Capstone Therapeutics, Inc. - "Importance of VLDL and Triglycerides in Cardiovascular Disease" Dec 16 2014
Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker... Dec 16 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 16 2014
Capstone Therapeutics Will Provide an Operating Update and Announces Third Quarter 2014 Financial... Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK